12:00 AM
Sep 07, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Daxas roflumilast: Additional Phase III data

Additional data from 2 double-blind, international Phase III trials (HERMES and AURA) showed that Daxas significantly improved mean pre-bronchodilator FEV1 by 48 mL vs. placebo (p<0.0001) and significantly reduced the rate of exacerbations that were moderate or severe per patient per year vs. placebo (1.14 vs. 1.37, p<0.0003). A total of 3,091 patients received placebo or 500 µg/day oral Daxas for up to 52 weeks. Data were published in The...

Read the full 328 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >